ArticleNature communications2024
Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 66 citations in OpenAlex.
- Prenatal Opioid Exposure and Subsequent Risk of Fractures in Children: An Emulated Target Trial Using a Nationwide Birth Cohort.Indian pediatrics · 2026Article
- Maternal opioid prescriptions and subsequent risk of hospital admission in offspring in South Korea: A nationwide birth cohort study.PLoS medicine · 2026Article
- Income Volatility and Risk of All-Cause Mortality and Cause-Specific Hospitalization Among Adults With Depression: A Nationwide Cohort Study.Journal of Korean medical science · 2026Article
- The acuity of paediatric asthma in the emergency department worsened after the COVID-19 pandemic in Alberta, Canada.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2026Article
- Association between residential greenness and the risk of inflammatory bowel disease in patients with COVID-19: A Korean nationwide cohort study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Reduced-dose dexamethasone premedication for weekly paclitaxel: a retrospective cohort study of early hypersensitivity reactions and steroid-related toxicity.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Systemic atopy and upper-airway disease define susceptibility to incident asthma after COVID-19 in Korea.Nature communications · 2026Article
- Residential Greenness and Risk of Coronary Artery Disease Following COVID-19: A Nationwide Cohort Study in South Korea.Journal of the American Heart Association · 2026Article
- Herpes zoster vaccination and cognitive disorders in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Global, regional, and national burden of chronic respiratory diseases among perimenopausal women, 1990-2021: an analysis for the Global Burden of Disease Study 2021.Journal of thoracic disease · 2026Article
- Observational
- Type I IFN-dependent FcγRIV signaling in murine monocytes promotes lethal anaphylaxis during viral infections.The Journal of clinical investigation · 2026Article
- Primed to overreact: virus-induced IFN contributes to antibody-mediated anaphylaxis.The Journal of clinical investigation · 2026Article
- Investigation of Biomarkers in Allergic Patients with Long COVID.Journal of personalized medicine · 2026Article
- Article
- New-onset allergic diseases after SARS-CoV-2 infection: mechanistic hypotheses and emerging strategies for risk stratification.Frontiers in immunology · 2026Review
- Characterization of adverse reactions to two antihistamine drugs: A descriptive analysis from WHO-VigiAccess.PloS one · 2026Article
- Incidence rates of allergy diagnoses in the U.S. military health system after the COVID-19 pandemic.Frontiers in allergy · 2026Article
- Article
- Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990-2023: a Global Burden of Disease study.Nature medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 4 countries.
Funding
Abstract
As mounting evidence suggests a higher incidence of adverse consequences, such as disruption of the immune system, among patients with a history of COVID-19, we aimed to investigate post-COVID-19 conditions on a comprehensive set of allergic diseases including asthma, allergic rhinitis, atopic dermatitis, and food allergy. We used nationwide claims-based cohorts in South Korea (K-CoV-N; n = 836,164; main cohort) and Japan (JMDC; n = 2,541,021; replication cohort A) and the UK Biobank cohort (UKB; n = 325,843; replication cohort B) after 1:5 propensity score matching. Among the 836,164 individuals in the main cohort (mean age, 50.25 years [SD, 13.86]; 372,914 [44.6%] women), 147,824 were infected with SARS-CoV-2 during the follow-up period (2020-2021). The risk of developing allergic diseases, beyond the first 30 days of diagnosis of COVID-19, significantly increased (HR, 1.20; 95% CI, 1.13-1.27), notably in asthma (HR, 2.25; 95% CI, 1.80-2.83) and allergic rhinitis (HR, 1.23; 95% CI, 1.15-1.32). This risk gradually decreased over time, but it persisted throughout the follow-up period (≥6 months). In addition, the risk increased with increasing severity of COVID-19. Notably, COVID-19 vaccination of at least two doses had a protective effect against subsequent allergic diseases (HR, 0.81; 95% CI, 0.68-0.96). Similar findings were reported in the replication cohorts A and B. Although the potential for misclassification of pre-existing allergic conditions as incident diseases remains a limitation, ethnic diversity for evidence of incident allergic diseases in post-COVID-19 condition has been validated by utilizing multinational and independent population-based cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.